Saturday, June 24, 2017

Practice Management Program III

Chair:  Evert Tuyp, MD, FRCPC

The third and final of the three Practice Management sessions offer expert answers to questions on why do research, how to write an article and how to get published as well as opportunities to discuss a number of medico-political issues through a series of vignettes.

07:00-07:10 Welcome & Agenda Evert Tuyp
07:10-07:29 Why do Research & How to Write an Article for a Journal Jerry Tan
 07:29-07:49 How to Get Published Kirk Barber
07:49-08:28 Practice Management Vignettes Robert Richards
08:28-08:30 Closing Remarks Evert Tuyp


Accredited Breakfast Symposium

Co-developed by AbbVie and the CDA

The Clock is Ticking: The Risks of Waiting

Many specialties treat patients where the goal is to decrease systemic inflammation.  Frequently, the window of intervention is time sensitive for optimal patient outcomes. Through this symposium, participants will explore the data that supports the strategy that early identification and diagnosis, followed by early initiation of an optimal treatment improves the success of achieving better patient outcomes.  Additional data will be presented from the perspective of other specialties (rheumatology, cardiology and surgery) that also treat dermatology patients.


Plenary 4 – Social Media and Networking

Moderator:  Andy Steggles

Whether you want to brand yourself or your business, today’s digital world brings with it interesting opportunities and challenges.  This session will look at how you can use social media and social networking to generate deeper engagement and more meaningful interactions.  Through shared stories with colleagues and tips from a social networking expert, you will learn ideal strategies to position yourself and what pitfalls to avoid.

10:10-10:15 Introduction & Welcome Remarks Andy Steggles
10:15-10:50 Panel Discussion Bolu Ogunyemi, Harvey Lui, TBC
10:50-10:55 Q&A


New Investigators Program

Chair:  Alain Brassard, MD, FRCPC

This program highlights the research of residents and early career dermatologists (within seven years of certification) who have demonstrated the qualities that will make them leaders of our specialty in Canada and internationally in the future. The purposeful selection of speakers that represent a broad spectrum of experience – from the residency years to the early years as independent practitioners – will hopefully bring to life in our residents and dermatologists the element of excitement and thrill that a budding career entails.

11:05-11:10 Welcome & Introduction Alain Brassard
11:10-11:20 Comprehensive Analysis of Cutaneous T-Cell Lymphoma (CTCL) Incidence and Mortality in Canada Ivan V. Litvinov
11:20-11:30 The Management of Fibro-Adipose Vascular Anomalies (FAVA) at a Tertiary Referral Centre: The Great Ormond Street Experience Rosalind Ashton
11:30-11:40 Does Ectopic Expression of Germ Cell Proteins Contribute to Genomic Instability in Cutaneous T-Cell Lymphomas? Ivan V. Litvinov
11:40-11:50 Incidence of Skin Tattooing with the use of Ferric Chloride as a Topical Hemostatic Agent Mohammad Pannu
11:50-12:00 Gene expression analysis in CTCL highlights disease heterogeneity and identifies potential diagnostic and prognostic indicators Ivan V. Litvinov
12:00-12:10 An Evaluation of the Quality of Life, Treatments, and Resources Available for Patients with Psoriasis in Canada: A Comparison of Biologic and Non-Biologic Users Arvin Ighani
12:10-12:20 A systematic review on oral isotretinoin therapy and clinically observed wound healing in acne patients Katherine A. McDonald
12:20-12:30 Q&A & Closing remarks Alain Brassard


Luncheon Symposium

Co-developed by Sanofi Genzyme and the CDA

Evolving Perspectives in Atopic Dermatitis: Do We Need New Treatment Options?

The management of moderate-to-severe atopic dermatitis (AD) in adults who fail to respond to topical therapies and phototherapy remains a clinical challenge for dermatologists, and a frustration for patients living with this disease. Currently, systemic immunosuppressive therapies that broadly target the immune system are used off-label in Canada for difficult-to-treat AD. In recent years, exciting advances in our understanding of the immunopathogenesis of AD have uncovered new targets for treatment. Several targeted therapies are now in clinical development and one is already approved by the FDA, with Phase 2 and Phase 3 studies demonstrating a new level of efficacy in adults with moderate-to-severe AD. These targeted therapies are poised to address the substantial unmet needs and burden of disease in patients living with moderate-to-severe AD.

12:40-12:45 Introduction, overview & objectives Melinda Gooderham
12:45-12:55 New data on the burden of moderate-to-severe AD in adults: results of a recent survey by the Eczema Society of Canada Amanda Cresswell-Melville
12:55-13:15 Evolving concepts in the immunopathogenesis and clinical burden of atopic dermatitis Melinda Gooderham
13:15-13:30 The current landscape of managing adults with moderate-to-severe AD: Are we doing enough for our patients? Ron Vender
13:30-13:45 A look to the future: Evidence for emerging targeted treatments for moderate-to-severe AD in adults Yves Poulin
13:45-13:50 Summary & chair perspectives Melinda Gooderham
13:50-14:10 Panel discussion/questions & answers Melinda Gooderham


Cosmetic Workshop

Chair:  Vince Bertucci, MD, FRCPC


Through patient demonstrations and videos, this workshop will review anatomical features that are key to safe and optimal injection of fillers and neurotoxins and discuss approaches and strategies for achieving the most desirable results.

CDF Annual General Meeting


CDF Reception


Child and Youth Fun Dinner


CDA Awards Reception and Ceremony


CDA President’s Banquet